title: American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.
abstract: OBJECTIVE
  To update the recommendations on the role of bone-modifying agents in the prevention and treatment of skeletal-related events (SREs) for patients with metastatic breast cancer with bone metastases.
  
  
  METHODS
  A literature search using MEDLINE and the Cochrane Collaboration Library identified relevant studies published between January 2003 and November 2010. The primary outcomes of interest were SREs and time to SRE. Secondary outcomes included adverse events and pain. An Update Committee reviewed the literature and re-evaluated previous recommendations.
  
  
  RESULTS
  Recommendations were modified to include a new agent. A recommendation regarding osteonecrosis of the jaw was added.
  
  
  CONCLUSIONS
  Bone-modifying agent therapy is only recommended for patients with breast cancer with evidence of bone metastases; denosumab 120 mg subcutaneously every 4 weeks, intravenous pamidronate 90 mg over no less than 2 hours, or zoledronic acid 4 mg over no less than 15 minutes every 3 to 4 weeks is recommended. There is insufficient evidence to demonstrate greater efficacy of one bone-modifying agent over another. In patients with a calculated serum creatinine clearance of more than 60 mg/min, no change in dosage, infusion time, or interval of bisphosphonate administration is required. Serum creatinine should be monitored before each dose. All patients should receive a dental examination and appropriate preventive dentistry before bone-modifying agent therapy and maintain optimal oral health. Current standards of care for cancer bone pain management should be applied at the onset of pain, in concert with the initiation of bone-modifying agent therapy. The use of biochemical markers to monitor bone-modifying agent use is not recommended.
authors.affiliation: University of Michigan, Ann Arbor, MI, USA.
authors.forename: Catherine H
authors.initials: CH
authors.lastname: Van Poznak
authors.forename: Sarah
authors.initials: S
authors.lastname: Temin
authors.forename: Gary C
authors.initials: GC
authors.lastname: Yee
authors.forename: Nora A
authors.initials: NA
authors.lastname: Janjan
authors.forename: William E
authors.initials: WE
authors.lastname: Barlow
authors.forename: J Sybil
authors.initials: JS
authors.lastname: Biermann
authors.forename: Linda D
authors.initials: LD
authors.lastname: Bosserman
authors.forename: Cindy
authors.initials: C
authors.lastname: Geoghegan
authors.forename: Bruce E
authors.initials: BE
authors.lastname: Hillner
authors.forename: Richard L
authors.initials: RL
authors.lastname: Theriault
authors.forename: Dan S
authors.initials: DS
authors.lastname: Zuckerman
authors.forename: Jamie H
authors.initials: JH
authors.lastname: Von Roenn
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000628:therapy; D000069448:Denosumab; D004164:Diphosphonates / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D000077268:Pamidronate; D053245:RANK Ligand / Q000627:therapeutic use; D012955:Societies, Medical; D015996:Survival Rate; D016896:Treatment Outcome; D000077211:Zoledronic Acid
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D053245:RANK Ligand; D000069448:Denosumab; D000077211:Zoledronic Acid; D000077268:Pamidronate